|
HCV DAA Costs & Use Gilead Millman Report
 
|
|
|
Download the PDF here  
This report discusses the reduction in cost per treatment regimen from $84,000 in 2013 to an average net cost of approximately $11,500 to $17,0001 in mid-2020, based on available data across key segments and products.  
MILLIMAN WHITE PAPER  
Analysis of prescription drugs for the treatment of hepatitis C in the United States 1 May 2021  
A study of the evolution of second-generation direct-acting antivirals to treat hepatitis C virus from mid-
2014 to mid-2020  
Commissioned by Gilead Sciences, Inc.
![0809231](../images/080923/080923-4/0809231.gif)
![0809232](../images/080923/080923-4/0809232.gif)
![0809233](../images/080923/080923-4/0809233.gif)
| |
|
|
|
|
|